An observational study in Alcoholic Liver Cirrhosis, sponsored by Pharmicell Co., Ltd.. Recruiting at 14 sites in South Korea. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Pharmicell Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.
The main question it aims to answer is:
- Do adverse event of special interest (AESI) or liver transplantation occur during the 5 years after Cellgram-LC administration?
Participants who previously received Cellgram-LC in the PMC-P-07 study and voluntarily consent to participate in this long-term follow-up study will be followed for 5 years after Cellgram-LC administration through telephone visits to collect information on AESI and liver transplantation.
45 studies on the registry are indexed under Liver Cirrhosis, Alcoholic; 14 are open to participants now.
This study's planned enrollment of 100 is below the median of 142 across 19 observational studies indexed under Liver Cirrhosis, Alcoholic.
Browse Liver Cirrhosis, Alcoholic studies →Pharmicell Co., Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 clinical trial and voluntarily consent to participate in this long-term follow-up study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- None.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who previously received Cellgram-LC in the PMC-P-07 study and voluntarily provide written informed consent to participate in this long-term follow-up study.
Incidence of Adverse Event of Special Interest (AESI)
Adverse event of special interest (AESI) include death, neoplasm or malignancy in any tissue or organ, immune reactions including worsening of pre-existing autoimmune disease or new-onset autoimmune disease, and other delayed adverse events considered related to Cellgram-LC.
Time frame: From the date of Cellgram-LC administration through 5 years after administration, assessed annually.
Occurrence of Liver Transplantation
The number and percentage of participants who undergo liver transplantation will be summarized during the 5-year follow-up period after Cellgram-LC administration.
Time frame: From the date of Cellgram-LC administration through 5 years after administration, assessed annually.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No — Individual participant data will not be made available to other researchers.
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pharmicell Co., Ltd.